<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440062</url>
  </required_header>
  <id_info>
    <org_study_id>EVIDIMS</org_study_id>
    <nct_id>NCT01440062</nct_id>
  </id_info>
  <brief_title>Efficacy of Vitamin D Supplementation in Multiple Sclerosis (EVIDIMS)</brief_title>
  <official_title>Phase II Study of Efficacy of Vitamin D Supplementation in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NeuroCure Clinical Research Center, Charite, Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Examination of efficacy, safety and tolerability of vitamin D3 in the treatment of Multiple
      Sclerosis (MS).
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">June 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy parameters</measure>
    <time_frame>1 day</time_frame>
    <description>efficacy of Vitamin D (high dose) in patients with Multiple Sclerosis compared to low dose of Vitamin D</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety &amp; tolerability parameters</measure>
    <time_frame>1 day</time_frame>
    <description>Routine laboratory, vital signs, physical examination, ECG, AE reporting, Quality of Life</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Verum (high dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>verum arm receiving high dose Vitamin D oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Verum (low dose)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>low dose arm receiving neutral oil and low dose of Vitamin D</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Verum arm receiving Vitamin D oil</intervention_name>
    <description>oil: 20000 IU/g tablet: 400 IU/g every second day</description>
    <arm_group_label>Verum (high dose)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day</intervention_name>
    <description>neutral oil and a low dose of vitamin D</description>
    <arm_group_label>Verum (low dose)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Age between 18 and 65 at randomization

          -  Relapsing-remitting MS according to the revised McDonald-Criteria (2005)

          -  EDSS ≤ 6,0

          -  Stable immunomodulatory treatment for at least 3 months

          -  Sufficient birth control (Pearl-Index &lt;1) and negative pregnancy test at
             screening/randomization

        Exclusion Criteria:

          -  Any other MS-course than RRMS

          -  Treatment with high dose vitamin D within 6 months prior to randomization

          -  Patients who have received over the last three months prior to randomization, an
             immunomodulatory therapy with the exception of IFN-β1b (Betaferon ®)

          -  Any condition that could interfere with MRI or other study related investigation

          -  Intolerability to Gd-DTPA

          -  Hypersensitivity to the drug Colecalciferol

          -  Patients with sarcoidosis

          -  Presence or history of nephrolithiasis

          -  Pseudohypoparathyroidism

          -  Clinically relevant dysfunction of liver, bone narrow or kidney defined by the
             following laboratory values:

               -  HB &lt;8.5 g / dl

               -  WBC &lt;2.5 / nl

               -  platelet count &lt;100/nl

               -  Creatinine clearance by Cockcroft-Gault formula: Cl &lt;110ml/min (male) and Cl
                  &lt;95ml/min (female)

               -  AST / ALT&gt; 3.5 times higher than the upper reference value

               -  bilirubin&gt; 2.0 mg / dl

               -  hypercalcaemia&gt; 2.7 mmol / l

               -  calcium / creatinine ratio in urine&gt; 1

          -  Treatment with hydrochlorothiazide, digitoxin, digoxin, phenytoin, barbiturates

          -  Pregnancy or lactation period

          -  Participation in any clinical study within 3 months before or at any time during study

          -  Any medical, psychiatric or other condition that could interfere with the patient's
             ability to understand and give the informed consent, to comply with the protocol or to
             finish the study any ruling commitment or placement in an institution
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan-Markus Dörr, Dr.</last_name>
    <role>Study Director</role>
    <affiliation>Charite</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan-Markus Dörr, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite-NeuroCure</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kliniken für Neurologie Teupitz/Lübben, Asklepios Fachkliniken Brandenburg GmbH</name>
      <address>
        <city>Teupitz</city>
        <state>Brandenburg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Praxis</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologisches Facharztzentrum</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Martha-Maria Halle-Dölau gGmbH</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sankt Josefs Krankenhaus Potsdam Neurologie</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2011</study_first_submitted>
  <study_first_submitted_qc>September 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Jan-Markus Dörr</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

